With a successful IPO and a lucrative partnership deal with Janssen under its belt, Sunstone-backed Alligator Biosciences is turning its focus on its proprietary pipeline and three promising candidate drugs.
Novo Ventures has taken the lead in a Series A financing round in a new US-based company developing medicine against the liver disease NASH – a disease that big as well as small companies have started to focus on, including Novo Nordisk.
The Danish biotech company Saniona receives their second milestone payment from The Michael J. Fox Foundation for Parkinson's Research after making new progress in the research on potential candidate drugs against Parkinson’s Disease.
Omega Funds receives 2200 applications from life science companies per year and 99.9 percent of these are turned down. But some Danish biotech companies have caught the attention of founder Otello Stampacchia and might be among the 0.1 lucky ones.
In the aftermath of the consolidation of its research and development activities, AstraZeneca has launched a new business incubator in Sweden. The project is partly state-funded and the drug company is very interested in welcoming Danish companies.
A Danish biotech company is now going to develop biomarkers for US-based drug group Bristol-Myers Squibb to potentially aid in diagnosing and monitoring fibrotic diseases, including fatty liver disease NASH.
For the third time, Novo A/S invests in Synlab, Europe’s biggest company for laboratory analyses. Previously, Novo A/S has not wanted to disclose the amount invested. But this time, the investment sum is revealed and it amounts to billions of Danish kroner.
A Mexican partner of the Danish biotech company Saniona has been approved to undertake a phase III study of the candidate drug tesofensine for treating obesity. CEO Jørgen Drejer describes this as the “most important milestone” since the company's beginning in April 2012.
Genmab’s CEO is ecstatic over the biotech's “shining star”, bone marrow cancer drug Darzalex. He doubts he will see anything like it in his time in the company, but is working intently on finding a new cash cow.
Norway-based financial services group DNB believes the Oslo Cancer Cluster has developed into one of Europe’s top biotech hubs. Norway’s life science industry is generally speaking more mature than a few years ago, says the group’s senior advisor for healthcare.
The global hearing device industry is currently benefitting from an ageing population. But what is going to drive growth when the demographic trend is reversed? MedWatch spoke to the Danish industry majors about the issue.